Toujeo lowers hypoglycemia among insulin treated people with type 2 diabetes
Toujeo lowers hypoglycemia among insulin-treated people with type 2 diabetes
click here to activate — for more information go to-http://www.netmd.in/category/diabetes/
A new observational study has shown that Toujeo insulin reduced events of hypoglycemia by 33 per cent compared to other basal insulins.Toujeo is a once-daily long-acting insulin made by Sanofi, the same company that makes Lantus.The results of the DELIVER 2 study, which involved 1,894 people, were released during the Endocrine Society 2017 Annual Meeting in Orlando, Florida, US.Riccardo Perfetti, who is head of Sanofi’s global diabetes medical team, said: “These results increase the body of evidence on the use of Toujeo in people with type 2 diabetes from observational studies. “While randomised clinical trials provide the highest level of evidence, comparative data from real-world observational studies can be relevant for […] evaluating how findings from clinical trials can translate into routine clinical practice.”The DELIVER 2 trial used data from 1,894 people with type 2 diabetes to test how effective Toujeo was during a six-month period.
for more information go to-http://diabetes-destroyer.netmd.in/
type 2 diabetes, clinical trials,Toujeo